Brooks Laboratories Ltd (BROOKS) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Brooks Laboratories Ltd on NSE and BSE, with an AI summary of each filing.
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 07 Nov 2026, 5:30 am
Brooks Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/11/2026 ,inter alia, to consider and approve the Unaudited Standalone ....
Intimation · 07 Nov 2026, 5:30 am
Brooks Laboratories Schedules Board Meeting on 7th Nov'26 for Q2 Financial Results Brooks Laboratories Limited announced that its Board of Directors will meet on 7th Nov'26 to consider and approve the unaudited standalone and consolidated financial results, along with the Limited Review Report, for the quarter and half-year ended 30th Sep'26. Additionally, the trading window for dealing in company securities, closed since 1st Oct'26 for designated persons and insiders, will reopen 48 hours after the declaration of the financial results.
Brooks Laboratories Limited has informed the BSE that the meeting of Board of Directors of the Company is scheduled on 07/11/2026, inter alia, to consider and approve take on records the ....
Others (Uncategorized) · 03 Nov 2026, 5:34 pm
Brooks Laboratories Board to Consider Q2 FY27 Financial Results on 7th Nov'26 Brooks Laboratories Limited announced that its Board of Directors will meet on 7th Nov'26 to consider and approve the unaudited standalone and consolidated financial results, along with the Limited Review Report, for the quarter and half-year ended 30th Sep'26. Additionally, the insider trading window, closed since 1st Oct'26, will reopen 48 hours following the declaration of the financial results.
BROOKS LABORATORIES LIMITED has informed the Exchange about Board Meeting to be held on 07-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 .
Intimation · 07 Nov 2026, 5:30 am
Outcome of Board Meeting under Regulation 30 of LODR for the Scheme of Arrangement
Others (Uncategorized) · 14 Oct 2026, 11:52 pm
Brooks Laboratories Approves Demerger of Manufacturing Business into Abridge Speciality Brooks Laboratories' board approved the demerger of its Manufacturing Business into wholly owned subsidiary Abridge Speciality Limited on a going-concern basis. The demerged unit generated ₹8,287.26 lakhs (96.66% of total turnover) in FY26. Shareholders will receive 1 fully paid equity share of Abridge Speciality for every 1 share held in Brooks Laboratories, maintaining proportional mirror shareholding (52.62% promoter, 47.38% public). Post-scheme, Abridge Speciality will list on BSE and NSE and be renamed Brooks Laboratories Limited, while the residual trading entity will be renamed Xuri Lifesciences Limited. Listing is expected ~16 months from filing.
Outcome of Board Meeting held on Wednesday, October 14, 2026
Others (Uncategorized) · 14 Oct 2026, 11:17 pm
Brooks Laboratories Approves Demerger of Manufacturing Business into Abridge Speciality The Board of Brooks Laboratories approved the demerger of its Manufacturing Business into wholly owned subsidiary Abridge Speciality on 14th Oct'26. The transferred unit contributed Rs. 8,287.26 lakhs in FY26, representing 96.66% of total revenue. Shareholders will receive 1 share of Abridge Speciality for every 1 share held in Brooks Laboratories, with identical shareholding mirror (52.62% promoter, 47.38% public). Post-demerger, Abridge Speciality will list on BSE and NSE and be renamed Brooks Laboratories, while the residual trading business will be renamed Xuri Lifesciences. Listing is targeted within ~16 months.
please find attached for clarification for movement in price
Others (Uncategorized) · 13 Oct 2026, 4:19 pm
Brooks Laboratories Clarifies Significant Share Price Movement Is Purely Market Driven In response to BSE's inquiry on 12th Oct'26 regarding price movement, Brooks Laboratories stated on 13th Oct'26 that it has disclosed all material information impacting operations and performance under Regulation 30 of SEBI LODR Regulations within required timelines. The company clarified it is unaware of any specific reasons behind the significant fluctuations in its share price and trading volumes, emphasizing that the movement is purely market-driven with no management involvement, and reiterated its ongoing adherence to all regulatory compliance requirements.
The Exchange has sought clarification from Brooks Laboratories Ltd on October 12, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant ....
Others (Uncategorized) · 12 Oct 2026, 11:05 pm
Resignation of Ms. Krutika Rane as Company Secretary and Compliance Officer of the Company with effect from 9th October 2026.
Change in Management · 17 Sept 2026, 12:15 am
Brooks Laboratories Announces Resignation of Company Secretary Krutika Rane Brooks Laboratories Limited announced the resignation of Ms. Krutika Rane from the position of Company Secretary and Compliance Officer (Key Managerial Personnel). Her resignation, submitted on 16th Sep'26 to pursue external career opportunities, will become effective at the close of business hours on 9th Oct'26.
Scrutinizer Report alongwith voting results for the AGM held on September 3, 2026.
Annual General Meeting · 05 Sept 2026, 2:05 am
Proceedings of the 24th AGM held on Thursday, September 3, 2026.
Annual General Meeting · 03 Sept 2026, 9:22 pm
Please find attached addendum to the notice of 24th Annual General Meeting.
Annual General Meeting · 21 Aug 2026, 10:24 pm
Addendum to the Notice of 24th Annual General Meeting of the Company.
Others (Uncategorized) · 21 Aug 2026, 10:21 pm
Financial Results for quarter ended June 30,2026.
Financial Result · 14 Aug 2026, 1:24 am
Brooks Laboratories Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Lakh) ■ Revenue: 2,296 (-10.0% YoY | +13.6% QoQ) ■ EBITDA: 186 (-40.4% YoY | +174.8% QoQ) ■ EBITDA Margin (%): 8.1 (-414 bps YoY | +476 bps QoQ) ■ PAT: -179 (Profit to Loss YoY | Profit to Loss QoQ) ■ EPS (INR): -0.61 (Profit to Loss YoY | Profit to Loss QoQ) Brooks Laboratories Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Lakh) Segmental Performance Trading ■ Revenue: 18.5 (-48.8% YoY | -20.2% QoQ) ■ EBIT: -13.8 (+2.8% YoY | -18.1% QoQ) ■ EBIT Margin (%): -74.4 (-3524 bps YoY | -2412 bps QoQ) Manufacturing ■ Revenue: 2,278 (-9.4% YoY | +14.0% QoQ) ■ EBIT: 185 (-40.8% YoY | +110.0% QoQ) ■ EBIT Margin (%): 8.1 (-430 bps YoY | +371 bps QoQ)
Outcome of Board Meeting held on Thursday, 13th August, 2026
Outcome · 14 Aug 2026, 1:20 am
Brooks Labs Posts Q1 Net Loss on JCE Drag, Revenue Declines YoY Brooks Laboratories reported a consolidated net loss of Rs. 178.69 Lakhs for Q1FY27, compared to a profit of Rs. 958.48 Lakhs in Q1FY26. The loss was primarily driven by a Rs. 320.55 Lakh share of loss from its jointly controlled entity. Consolidated revenue from operations for the quarter ended 30th Jun'26 fell 9.99% YoY to Rs. 2,296.08 Lakhs. The standalone business remained profitable, posting a PAT of Rs. 141.86 Lakhs. Consolidated EPS stood at Rs. (0.61) versus Rs. 3.25 a year ago.
Letter to the Shareholders-Annual Report for the FY 2025-26
Annual Report · 12 Aug 2026, 11:44 pm
Notice of 24th Annual General Meeting of the Company to be held on 3rd September 2026 through VC/OAVM.
Annual General Meeting · 12 Aug 2026, 11:39 pm
Pursuant to Regulation 34 read with Regulation 30 of SEBI Listing Regulations, we are enclosing herewith the following: 1. Notice of the AGM.2. Annual Report for the Financial Year 2025-26.
Others (Uncategorized) · 12 Aug 2026, 11:35 pm
Brooks Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 ,inter alia, to consider and approve and take on record the ....
Intimation · 13 Aug 2026, 5:30 am
Brooks Laboratories Board Meeting for Q1FY27 Results on 13th Aug'26 Brooks Laboratories (NSE: BROOKS) has scheduled a Board of Directors meeting on 13th Aug'26 to consider and approve the unaudited standalone and consolidated financial results for the quarter ending 30th Jun'26. In connection with the results, the trading window for designated persons has been closed since 1st Jul'26 and will reopen 48 hours after the financial results are declared.
Appointment of Mr. Rajesh Mahajan as President - Trading.
Change in Management · 17 Jul 2026, 10:59 pm
Brooks Laboratories Appoints New President of Trading Brooks Laboratories (NSE: BROOKS) has appointed Mr. Rajesh Mahajan as President - Trading and Senior Management Personnel, effective 17 Jul'26. Mr. Mahajan brings over 20 years of pharmaceutical industry experience, holding a Bachelor's in Biology and an MBA in Marketing. He has extensive expertise in pharmaceutical formulations and manufacturing operations and has been instrumental in the growth of the company's formulation business, including new project execution and business development initiatives. The appointment is a key management personnel change under SEBI regulations.
We hereby inform that, further to the disclosure made by the Company on 19th June 2026 regarding proposed sale of a portion of its shareholding in Brooks Steriscience Limited.
Others (Uncategorized) · 16 Jul 2026, 11:56 pm
Brooks Labs Executes MoU for Partial Stake Sale in JV Brooks Laboratories signed a binding MoU with Steriscience Specialties regarding the partial sale of its stake in its JV, Brooks Steriscience Limited (BSL). The company’s holding in BSL will decrease from 49.00% to 32.67% post-transaction. The deal is expected to generate an immediate cash inflow of approximately INR 106.33 crores, which will be utilized for growth and expansion. The MoU, valid for two years, establishes a value protection framework ensuring the remaining 32.67% stake is valued at no less than USD 22.87 million.
Intimation of Incorporation of Wholly Owned Subsidiary.
Others (Uncategorized) · 03 Jul 2026, 12:00 am
Brooks Laboratories Incorporates Wholly Owned Subsidiary Brooks Laboratories incorporated a wholly owned subsidiary, Abridge Speciality Limited, on 2nd Jul'26. The new entity has an authorized share capital of Rs. 100,000 and will operate in the manufacturing and marketing of pharmaceuticals. This strategic move aims to expand the company's business operations. As a newly incorporated entity, it has no turnover or net worth history. Brooks Laboratories will hold 100% of the share capital, making it a related party transaction. The initial capital was subscribed in cash at face value.
With reference to corporate announcement titled "Partial Sale of Equity Shares held in Brooks Steriscience Limited" submitted by the Company on 19th June 2026, we wish to inform you that ....
Others (Uncategorized) · 20 Jun 2026, 8:36 pm
Brooks Labs to Partially Divest Stake in Subsidiary for ₹106.33 Crore On 19th Jun'26, Brooks Laboratories approved the partial monetization of its investment in Brooks Steriscience Limited. The company will sell 51,220 equity shares (16.33% stake) to Steriscience Specialties Private Limited for ₹20,760 per share, aggregating to ₹106.33 crore. Post-transaction, Brooks Labs' holding in the subsidiary will reduce from 49.00% to 32.67%. The proceeds will fund growth strategies, including operational expansion and capacity enhancement. This is not a related-party transaction.
We hereby inform that the Company at its board meeting held today i.e 19th June 2026 has approved sale of 51,220 equity shares held by the Company in Brooks Steriscience Limited to Steriscience ....
Others (Uncategorized) · 20 Jun 2026, 3:02 am
Brooks Laboratories to Partially Divest Stake in Subsidiary for ₹106.33 Crore On 19th Jun'26, Brooks Laboratories' board approved the sale of 51,220 equity shares (a 16.33% stake) in its subsidiary, Brooks Steriscience Limited, to Steriscience Specialties Private Limited. The transaction, valued at ₹106.33 crore (₹20,760 per share), is a partial monetization. Post-sale, Brooks Laboratories will retain a 32.67% stake, down from 49.00%. Proceeds will fund the company's growth strategy, including capacity expansion and funding business opportunities. The deal is not a related-party transaction.
Appointment of Chief Executive Officer.
Change in Management · 30 May 2026, 1:51 am
Brooks Laboratories Appoints Prashant Rathi as Chief Executive Officer Brooks Laboratories Limited appointed Mr. Prashant Rathi as Chief Executive Officer, effective 1st Jun'26. Mr. Rathi, who will continue in his existing role as Chief Financial Officer, is a Chartered Accountant and Company Secretary with over 13 years of experience in finance and accounting. Having been with the company for more than five years, his appointment leverages his in-depth understanding of the firm's operations and financial framework to drive future growth and strategic objectives.